Celgene appoints Wim Souverijns as vice president general manager for UK and Ireland
US biotech company Celgene (Nasdaq: CELG) has appointed Wim Souverijns as vice president general manager for the UK and Ireland.
He replaces Samantha Pearce who has become vice president and general manager for EMEA emerging markets.
Mr Souverijns said: “I have had the privilege of working for Celgene for a number of years and I am eager to continue our commitment here in the UK and Ireland to patients with cancer, inflammatory and immune-related diseases. Celgene UK and Ireland has helped many patients since its inception in 2006 and this is a particularly exciting time to join the team as we expand our inflammation and immunology portfolio.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze